Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:38-43.
doi: 10.2174/1874312901206010038. Epub 2012 Apr 26.

Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland

K Puolakka  1 , H Blåfield, M Kauppi, R Luosujärvi, R Peltomaa, T Leikola-Pelho, K Sennfalt, A Beresniak
Affiliations

Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland

K Puolakka et al. Open Rheumatol J. 2012.

Abstract

Objective: The main objective was to compare the cost-effectiveness of therapeutic options in moderate or severe rheumatoid arthritis (RA) when a clinical response to a first TNF-blocker, either etanercept (ETA), adalimumab (ADA), or infliximab (INF), is insufficient.

Methods: Effectiveness criteria were defined as remission (RS), low disease activity (LDAS), and moderate to high disease activity (MHDAS). Cost-effectiveness was derived as cost per day in RS and in LDAS using simulation modelling to assess six sequential biologic strategies over 2 years. Each sequential treatment strategy was composed of three biologic agents and included a first anti-TNF agent, ETA, ADA or INF, followed by either abatacept (ABA) or rituximab (RTX) as a second therapeutic option in case of an insufficient response, followed by another anti-TNF agent in case of further insufficient response.

Results: Over two years and taking into account biologic costs, the following estimated mean costs per day in RS and LDAS were respectively of €829 and €428 for the biologic sequence composed of ADA-ABA-ETA, €1292 and €516 for the sequence ADA-RTX-ETA, €829 and €429 for the sequence ETA-ABA-ADA, €1292 and €517 for the sequence ETARTX- ADA, €840 and €434 for the sequence INF-ABA-ETA, and €1309 and €523 for the sequence INF-RTX-ETA.

Conclusion: The treatment sequences including ABA as the second biologic option appear more cost-effective than those including RTX in a patients with moderate to severe RA and an insufficient response to a first anti-TNF agent.

Keywords: Cost-effectiveness; biologics; modelling.; rheumatoid arthritis.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Exemple of sequence A model structure with remission as effectiveness endpoint.
See this image and copyright information in PMC

References

    1. Puolakka K, Kautiainen H, Pohjolainen T, Virta L. Rheumatoid arthritis remains a threat to work productivity a nationwide registerbased uncidence study from finland. Scand J Rheumatol. 2010;39:436–8. - PubMed
    1. Hyrich K, Lunt M, Watson K, Symmons D, Silman A. Register BSfRB.Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20. - PubMed
    1. Gabriel S, Drummond M, Maetzel A. Omeract 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol. 2003;30:887–90. - PubMed
    1. Russell A, Beresniak A, Bessette L, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in dmards and anti-tnf inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol. 2008;28(4 ):403–12. - PubMed
    1. Genovese M, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis . 2008;67:547–54. - PubMed

LinkOut - more resources